Sort by: after hours % change | delayed % change | gain open | gain high | gain close | publishing date
tags : Liver symbols : Alny save search
Liver Disease Therapeutics Competitive Landscape and Market Forecasts to 2028
Published: 2024-02-12 (Crawled : 20:00) - prnewswire.com
ALPMY | News | $9.53 -1.11% 690K
|
Manufacturing
|
| O: 0.37%
H: 0.74%
C: 0.28%
BMY | $48.99 -0.31% 0.0% 9.1M
|
Health Technology
|
| O: -0.18%
H: 0.48%
C: -1.91%
ABBV | News | $169.54 0.98% -0.91% 4.1M
|
Health Technology
|
| O: 0.8%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: -0.06%
H: 0.0%
C: 0.0%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: 0.32%
H: 0.11%
C: -1.55%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -2.63%
H: 0.98%
C: -1.75%
liver disease therapeutics market
Non-Alcoholic Fatty Liver Disease Market to Observe Impressive Growth by 2032, Evaluates DelveInsight | Key Companies - MediciNova, Eli Lilly and Company, AstraZeneca, Madrigal Pharmaceuticals, BioMarin Pharmaceutical, GlaxoSmithKline, Pfizer
Published: 2024-01-22 (Crawled : 22:00) - prnewswire.com
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.51%
H: 0.37%
C: 0.32%
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 1.29%
H: 0.35%
C: -3.04%
HEPA | $1.47 4.26% 4.08% 71K
|
Health Technology
|
| O: -0.48%
H: 7.69%
C: 1.44%
ALT | $7.56 1.21% 1.19% 3.1M
|
Commercial Services
|
| O: -0.8%
H: 6.02%
C: 0.6%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.46%
H: 3.04%
C: 2.67%
ETNB | $8.92 -4.19% -4.37% 750K
|
Health Technology
|
| O: 1.19%
H: 0.63%
C: -0.72%
liver disease companies key growth market
Vir Biotechnology to Present New Data from Its Ongoing Phase 2 Chronic Hepatitis Delta and B Trials Today at AASLD’s The Liver Meeting® 2023
Published: 2023-11-13 (Crawled : 14:30) - biospace.com/
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 1.02%
H: 4.5%
C: 3.38%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.04%
H: 1.92%
C: 1.89%
meeting hepatitis liver ongoing trials today
Vir Biotechnology to Present Late-Breaking Data from Its Ongoing Phase 2 Chronic Hepatitis B and Delta Trials at AASLD’s The Liver Meeting® 2023
Published: 2023-11-10 (Crawled : 15:00) - biospace.com/
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 0.98%
H: 7.06%
C: 6.93%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.49%
H: 0.74%
C: -2.08%
meeting hepatitis liver ongoing trials
Vir Biotechnology Announces Multiple Abstracts Highlighting New Chronic Hepatitis B and Hepatitis Delta Data Accepted for Presentation at AASLD’s The Liver Meeting® 2023
Published: 2023-10-11 (Crawled : 12:00) - globenewswire.com
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -0.9%
H: 2.27%
C: 0.68%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.16%
H: 1.43%
C: 0.43%
meeting hepatitis liver presentation
Liver Cirrhosis Market to Observe Impressive Growth at a CAGR of 6.3% by 2032, Predicts DelveInsight
Published: 2023-07-12 (Crawled : 21:00) - prnewswire.com
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 1.7%
H: 0.01%
C: -0.32%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.08%
H: 0.46%
C: -1.26%
MDGL | $218.17 2.19% 2.15% 410K
|
Health Technology
|
| O: 0.41%
H: 3.34%
C: 1.43%
LPCN | $4.88 -3.75% -3.89% 76K
|
Health Technology
|
| O: 0.11%
H: 2.15%
C: 1.02%
GALT | $3.365 9.97% 9.06% 240K
|
Health Technology
|
| O: 0.64%
H: 7.01%
C: 5.1%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.69%
H: 1.02%
C: 0.29%
AKRO | $21.02 1.11% 1.09% 560K
|
Health Technology
|
| O: 0.78%
H: 1.1%
C: -0.15%
cirrhosis liver growth market
Regeneron Genetics Center Discovers Rare Mutations In The CIDEB Gene That Protect Against Liver Disease
Published: 2022-07-27 (Crawled : 22:00) - prnewswire.com
TEVJF | News | $12.37 -24.22% 380
|
Health Technology
|
| O: 2.86%
H: 0.0%
C: 0.0%
SNY | News | $47.69 1.15% 1.13% 1.7M
|
Health Technology
|
| O: 0.68%
H: 0.0%
C: 0.0%
REGN | News | $906.84 0.74% 0.74% 340K
|
Health Technology
|
| O: 0.17%
H: 0.53%
C: -1.11%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -3.5%
H: 6.04%
C: 4.76%
rare liver disease
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at the International Liver Congress™ 2022
Published: 2022-06-08 (Crawled : 12:00) - globenewswire.com
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 5.76%
H: 0.45%
C: -5.37%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 4.17%
H: 0.0%
C: 0.0%
hepatitis liver presentation international
Alnylam Announces Collaboration with Novartis to Explore Targeted Therapy to Restore Liver Function
Published: 2022-01-06 (Crawled : 13:00) - biospace.com/
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -3.19%
H: 0.0%
C: -3.32%
novartis announces collaboration liver therapy collaboration
Dicerna Presents Data From Phase 1 Trial of Belcesiran at American Association for the Study of Liver Diseases (AASLD) The Liver Meeting® 2021
Published: 2021-11-12 (Crawled : 14:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.47%
H: 0.0%
C: 0.0%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.49%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
disease liver disease phase 1 liver trial
Vir Biotechnology Presents New Data Evaluating the Potential for VIR-2218 and VIR-3434 to Achieve a Functional Cure for Chronic Hepatitis B Virus (HBV) Infection at AASLD The Liver Meeting®
Published: 2021-11-12 (Crawled : 13:15) - globenewswire.com
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: 4.66%
H: 0.0%
C: 0.0%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -2.06%
H: 0.0%
C: 0.0%
hepatitis potential biotech technology iot liver injection infections chronic hepatitis b
Vir Biotechnology Announces Multiple Abstracts Highlighting New Hepatitis B Data Accepted for Presentation at AASLD’s The Liver Meeting® 2021
Published: 2021-10-15 (Crawled : 14:00) - biospace.com/
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -0.02%
H: 3.08%
C: -2.81%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.34%
H: 0.09%
C: -0.69%
presentation hepatitis biotech technology iot liver
RNAi Roundtable: Liver-Directed RNAi Pipeline Programs
Published: 2021-09-20 (Crawled : 15:15) - alnylam.com
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: -1.25%
H: 0.1%
C: -2.4%
liver program
Dicerna Announces Interim Results From Phase 1 Trial of Belcesiran for Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-07-21 (Crawled : 13:00) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: 0.9%
H: 0.72%
C: 0.58%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: 0.58%
H: 0.42%
C: 0.38%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.45%
H: 0.0%
C: -2.13%
disease liver disease treatment phase 1 results liver trial phase 2 phase 3
Vir Biotechnology Presents New Clinical Data from Ongoing Trials of VIR-2218 and VIR-3434 in Patients with Chronic Hepatitis B Virus Infection at the International Liver Congress 2021
Published: 2021-06-25 (Crawled : 13:00) - globenewswire.com
VIR | $8.13 0.37% 0.37% 770K
|
Health Technology
|
| O: -0.52%
H: 1.36%
C: -7.74%
GILD | $67.03 0.12% 0.12% 5.2M
|
Health Technology
|
| O: -0.06%
H: 1.28%
C: 1.1%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.26%
H: 1.5%
C: 0.72%
hepatitis ongoing biotech technology iot liver trial injection infections chronic hepatitis b
Dicerna Initiates Patient Dosing in ESTRELLA Phase 2 Clinical Trial of Belcesiran for the Treatment of Alpha-1 Antitrypsin Deficiency-Associated Liver Disease
Published: 2021-06-22 (Crawled : 12:15) - biospace.com/
NVO | News | $128.64 2.7% -0.07% 3.7M
|
Health Technology
|
| O: -0.39%
H: 0.27%
C: -0.21%
LLY | News | $745.69 1.96% -0.16% 2M
|
Health Technology
|
| O: -0.02%
H: 0.44%
C: -0.53%
ALNY | $146.06 0.19% 0.18% 540K
|
Health Technology
|
| O: 0.08%
H: 1.01%
C: 0.9%
disease liver disease treatment phase 2 liver trial
Gainers vs Losers
| 78% | 22% |
Top 10 Gainers
MTTR | News 4 | $4.6 164.37% 62.17% 28M
|
AGBA | $2.94 135.2% 57.48% 66M
|
Finance
EDBL | News | $6.46 71.81% 41.8% 2M
|
MTC | $2.25 44.23% 30.67% 6M
|
Technology Services
OPRT | News | $3.175 41.11% 29.13% 12M
|
Finance
SHIM | $3.05 35.56% 26.23% 1.1M
|
HKIT | $1.345 31.86% 24.16% 390K
|
Technology Services
ABVC | $1.36 30.77% 23.53% 7.4M
|
Wholesale Trade
OST | $0.512 28.0% 21.88% 290K
|
POET | $1.59 27.2% 21.38% 4.2M
|
Manufacturing
Your saved searches
Save your searches and get alerts when important news are released.